Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 6 of 8 for:    ZX008 | Dravet Syndrome

ZX008 Expanded Access Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03780127
Expanded Access Status : Available
First Posted : December 19, 2018
Last Update Posted : August 26, 2019
Information provided by (Responsible Party):
Zogenix, Inc.

Brief Summary:
The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 clinical trials.

Condition or disease Intervention/treatment
Dravet Syndrome Drug: Fenfluramine Hydrochloride

Detailed Description:

The treatment plan consists of an up to 12-month Treatment Period. Access is via application by your health care provider and available at one of the Expanded Access treatment centers. The dose of ZX008 for the duration of the Treatment Period will range from 0.2 mg/kg/day to a maximum of 0.8 mg/kg/day, not to exceed a total daily dose of 30 mg/day; for patients concurrently being prescribed stiripentol, the maximum will be 0.5mg/kg/day, not to exceed a total daily dose of 20 mg/day.

The fenfluramine US Expanded Access Program (US EAP) is available to full-time US Residents only.

Participation in the US EAP is limited to patients currently residing in the US. Residency in the US must be for the duration of participation in the US EAP. Drug may not be shipped outside the US.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
Official Title: ZX008 Expanded Access Protocol - Dravet Syndrome Treatment Plan

Intervention Details:
  • Drug: Fenfluramine Hydrochloride
    ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
    Other Name: ZX008

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patient is male or female, age 2 years and older, inclusive as of Study Day 1.
  • Patient is diagnosed with Dravet syndrome.
  • Patient is experiencing convulsive seizures which are not controlled by current AEDs.
  • Patient is receiving at least one AED and will remain on at least one AED for the duration of treatment.
  • Patient has been approved for inclusion by Zogenix.

Exclusion Criteria:

  • Patient requires or starts using an unacceptable or contraindicated concomitant medication.
  • Patient has valvulopathy.
  • Patient is at risk for pulmonary hypertension.
  • Patient exclusion will be at the sole discretion of the Sponsor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03780127

Layout table for location contacts
Contact: ZX008 Clinical Trials Information Desk 510-338-9968

Sponsors and Collaborators
Zogenix, Inc.

Layout table for additonal information
Responsible Party: Zogenix, Inc. Identifier: NCT03780127    
Other Study ID Numbers: ZX008-1800
First Posted: December 19, 2018    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Epileptic Syndromes
Epilepsies, Myoclonic
Pathologic Processes
Epilepsy, Generalized
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs